Cardiff Oncology, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $104,000 (-14.0% year over year) and diluted EPS of -$0.14. It usually reports 29–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-14.0%
|
-9
+33.8%
|
-0.14
+33.3%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-62.4%
|
-12
+8.1%
|
-0.18
+10.0%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-27.3%
|
-11
+5.0%
|
-0.17
+32.0%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-25.8%
|
-14
-18.4%
|
-0.21
+19.2%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
-46.8%
|
-13
-34.2%
|
-0.20
+9.1%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
-3.2%
|
-12
-26.2%
|
-0.22
-4.1%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
+17.0%
|
-12
-21.8%
|
-0.25
-13.6%
|
|
Aug 8, 2024
39 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRDF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1213037
- Former names
- Trovagene, Inc. (until May 7, 2020); TrovaGene Inc. (until Mar 4, 2013); XENOMICS INC (until Jun 3, 2009); USED KAR PARTS INC (until Jun 30, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.